Aprea Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
APR-1051 showed early activity, tolerability, and a ~17-hour half-life; development is focused on biomarker-led dose expansion, with escalation expected to finish by H1 next year. ATRN-119 is shifting to combination studies, and cash runway extends to Q1 2028.
-
WEE1 inhibition may exploit DNA-repair vulnerabilities in biomarker-defined cancers, but clinical potential depends on manageable toxicity and durable activity. APR-1051’s fall trial update was expected to report enrollment and patient experience.
-
The session highlighted progress in synthetic lethality oncology, with a WEE1 inhibitor showing promising efficacy and safety in biomarker-defined cancers. Dose escalation established 150 mg as the minimum efficacious dose, and further data updates are expected in Q4.
-
The meeting covered director elections, auditor ratification, a reverse stock split, and executive compensation, with all proposals approved by stockholders. No questions were raised, and final voting results will be filed in a Form 8-K.
-
A precision oncology program targeting the DNA damage response pathway shows early clinical efficacy and strong tolerability, with partial responses in biomarker-selected patients and a favorable safety profile. Dose escalation and cohort expansion are ongoing, supported by recent financing and a robust cash runway.
Fiscal Year 2025
-
The session highlighted progress in precision oncology, with ongoing clinical trials for WEE1 and ATR inhibitors showing early signs of efficacy and strong biomarker-driven strategies. Key data readouts and new target disclosures are expected by early 2025.
Fiscal Year 2024
-
APR-1051, a selective oral WEE1 inhibitor, was designed to avoid PLK inhibition, addressing safety concerns seen with other WEE1 inhibitors. Early clinical data show no FDA concerns, and the phase 1 trial is underway with a safety update expected in Q4 2024.